- Conditions
- Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
- Interventions
- Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
- Drug · Diagnostic Test
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Houston, Texas • Temple, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder, Incontinence, Urge, Incontinence, Urinary, Incontinence
- Interventions
- Tolterodine Tartrate ER, Mirabegron, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Palo Alto, California • San Francisco, California
- Conditions
- Urgency Urinary Incontinence
- Interventions
- Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox]
- Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 2 more
- Conditions
- Overactive Bladder
- Interventions
- Vibegron, placebos, Tolterodine Tartrate ER
- Drug
- Lead sponsor
- Urovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 107
- States / cities
- Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 90 more
- Conditions
- Obesity
- Interventions
- Vibegron, Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Overactive Bladder
- Interventions
- Vibegron
- Drug
- Lead sponsor
- Urovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 64
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Tempe, Arizona + 54 more
- Conditions
- Nocturia
- Interventions
- TolterodineTartrate ER, Mirabegron, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Obesity
- Interventions
- beta3-adrenergic receptor agonist
- Drug
- Lead sponsor
- Aaron Cypess
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Vibegron
- Drug
- Lead sponsor
- Urovant Sciences GmbH
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Mirabegron, B Complex Plus Vitamin C Tablets
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Overactive Bladder
- Interventions
- vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
- Drug
- Lead sponsor
- Urovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 191
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more